UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| | | |
| Date of Report (Date of Earliest Event Reported): | | November 13, 2007 |
NASTECH PHARMACEUTICAL COMPANY INC.
__________________________________________
(Exact name of registrant as specified in its charter)
| | | |
| Delaware | 0-13789 | 11-2658569 |
_____________________
(State or other jurisdiction | _____________
(Commission | ______________
(I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| | | |
| 3830 Monte Villa Parkway, Bothell, Washington | | 98021 |
_________________________________
(Address of principal executive offices) | | ___________
(Zip Code) |
| | | |
| Registrant’s telephone number, including area code: | | 425-908-3600 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On November 13, 2007, Nastech Pharmaceutical Company Inc. (the "Company") issued two press releases announcing its corporate restructuring initiatives aimed at reducing operating expenses and enhancing shareholder value, including the establishment of MDRNA, Inc., its wholly-owned subsidiary, as an independent, separately financed company, and the concentration of its resources on Phase 2 clinical and partnered programs for PYY(3-36) Nasal Spray for obesity, Insulin Nasal Spray for type 2 diabetes, and PTH(1-34) Nasal Spray for osteoporosis.
Copies of these press releases are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | NASTECH PHARMACEUTICAL COMPANY INC. |
| | | | | |
| November 14, 2007 | | By: | | Dr. Steven C. Quay
|
| | | | |
|
| | | | | Name: Dr. Steven C. Quay |
| | | | | Title: Chairman of the Board, President and Chief Executive Officer |
Exhibit Index
| | | |
| Exhibit No. | | Description |
| |
|
99.1 | | Press Release of Nastech Pharmaceutical Company Inc. dated November 13, 2007. |
99.2 | | Press Release of Nastech Pharmaceutical Company Inc. dated November 13, 2007. |
